Prognostic value of inflammatory biomarkers for predicting the extent of lung involvement and final clinical outcome in patients with COVID-19.
COVID-19
Computed tomography
death
inflammation
inflammatory
mortality
prognosis
survival
Journal
Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences
ISSN: 1735-1995
Titre abrégé: J Res Med Sci
Pays: India
ID NLM: 101235599
Informations de publication
Date de publication:
2021
2021
Historique:
received:
31
12
2020
revised:
28
03
2021
accepted:
25
05
2021
entrez:
7
2
2022
pubmed:
8
2
2022
medline:
8
2
2022
Statut:
epublish
Résumé
Inflammation plays a major role in coronavirus disease (COVID-19). Factors that convey information about the status of inflammation could predict disease severity and help identify patients prone to clinical deterioration. Here, we aimed to evaluate the predictive value of inflammatory markers on the extent of lung involvement and survival of patients with COVID-19. Eighty patients with confirmed COVID-19 were enrolled. Demographic, clinical, and laboratory data were collected at admission. All patients underwent chest computed tomography (CT); the extent of lung involvement was assessed by a scoring system. Patients were followed up until death or discharge occurred. Logistic regression analysis was performed to evaluate the association of investigated variables with COVID-19-related death. The association between different variables and CT score was assessed using linear regression model. Receiver operator characteristic curve analysis was applied to identify the predictive value of inflammatory markers and CT score on survival. The mean age of patients was 54.2 ± 15.2 years; 65% were male. Increased neutrophil-to-lymphocyte ratio (β =0.69, odds ratio [OR] =1.50), platelet-to-lymphocyte ratio (β =0.019, OR = 1.01), and decreased lymphocyte to C-reactive protein ratio (LCR) (β = -0.35, OR = 0.62) were significantly associated with a higher CT score and increased odds of death ( Daily-performed laboratory tests that represent inflammation have great value for predicting the amount of disease burden and risk of mortality. Moreover, their cost-effectiveness and feasibility turn them into ideal prognostic markers.
Sections du résumé
BACKGROUND
BACKGROUND
Inflammation plays a major role in coronavirus disease (COVID-19). Factors that convey information about the status of inflammation could predict disease severity and help identify patients prone to clinical deterioration. Here, we aimed to evaluate the predictive value of inflammatory markers on the extent of lung involvement and survival of patients with COVID-19.
MATERIALS AND METHODS
METHODS
Eighty patients with confirmed COVID-19 were enrolled. Demographic, clinical, and laboratory data were collected at admission. All patients underwent chest computed tomography (CT); the extent of lung involvement was assessed by a scoring system. Patients were followed up until death or discharge occurred. Logistic regression analysis was performed to evaluate the association of investigated variables with COVID-19-related death. The association between different variables and CT score was assessed using linear regression model. Receiver operator characteristic curve analysis was applied to identify the predictive value of inflammatory markers and CT score on survival.
RESULTS
RESULTS
The mean age of patients was 54.2 ± 15.2 years; 65% were male. Increased neutrophil-to-lymphocyte ratio (β =0.69, odds ratio [OR] =1.50), platelet-to-lymphocyte ratio (β =0.019, OR = 1.01), and decreased lymphocyte to C-reactive protein ratio (LCR) (β = -0.35, OR = 0.62) were significantly associated with a higher CT score and increased odds of death (
CONCLUSION
CONCLUSIONS
Daily-performed laboratory tests that represent inflammation have great value for predicting the amount of disease burden and risk of mortality. Moreover, their cost-effectiveness and feasibility turn them into ideal prognostic markers.
Identifiants
pubmed: 35126578
doi: 10.4103/jrms.JRMS_1160_20
pii: JRMS-26-115
pmc: PMC8765511
doi:
Types de publication
Journal Article
Langues
eng
Pagination
115Informations de copyright
Copyright: © 2021 Journal of Research in Medical Sciences.
Déclaration de conflit d'intérêts
There are no conflicts of interest.
Références
J Natl Cancer Inst. 2014 May 29;106(6):dju124
pubmed: 24875653
N Engl J Med. 2020 Mar 26;382(13):1199-1207
pubmed: 31995857
Clin Infect Dis. 2020 Jul 28;71(15):762-768
pubmed: 32161940
Arch Intern Med. 2000 Mar 27;160(6):861-8
pubmed: 10737287
Jpn J Clin Oncol. 2020 Sep 28;50(10):1141-1149
pubmed: 32564084
J Med Virol. 2020 Jul;92(7):791-796
pubmed: 32181911
Clin Biochem Rev. 2004 May;25(2):121-32
pubmed: 18458712
Clin Rheumatol. 2020 Jul;39(7):2085-2094
pubmed: 32474885
Eur Radiol. 2020 Aug;30(8):4407-4416
pubmed: 32215691
J Infect. 2016 Nov;73(5):468-475
pubmed: 27519621
J Med Virol. 2020 Sep;92(9):1533-1541
pubmed: 32181903
Br J Haematol. 2020 Jul;190(2):e61-e64
pubmed: 32420612
Radiology. 2020 Aug;296(2):E115-E117
pubmed: 32073353
Mediators Inflamm. 2016;2016:8191254
pubmed: 27110067
Crit Rev Clin Lab Sci. 2020 Sep;57(6):389-399
pubmed: 32503382
Pathogens. 2020 Jun 20;9(6):
pubmed: 32575786
Clin Chim Acta. 2020 Jul;506:145-148
pubmed: 32178975
J Med Virol. 2020 Oct;92(10):1733-1734
pubmed: 32242950
Am J Emerg Med. 2020 Sep;38(9):1722-1726
pubmed: 32738466
Cell Cycle. 2011 Apr 15;10(8):1271-86
pubmed: 21512313
Front Med (Lausanne). 2020 Jun 09;7:301
pubmed: 32582743
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Front Immunol. 2020 Jun 16;11:1446
pubmed: 32612617
Future Oncol. 2010 Jan;6(1):149-63
pubmed: 20021215
BMJ Open. 2019 Jan 25;9(1):e022896
pubmed: 30782690
Lancet Infect Dis. 2013 Sep;13(9):752-61
pubmed: 23891402
BMJ. 2020 Apr 7;369:m1328
pubmed: 32265220
Scand J Clin Lab Invest. 2020 Nov;80(7):536-540
pubmed: 32804580
Int J Mol Sci. 2020 Jul 06;21(13):
pubmed: 32640747
Eur Radiol. 2020 Dec;30(12):6808-6817
pubmed: 32623505
Clin Infect Dis. 2020 Sep 12;71(6):1393-1399
pubmed: 32271369
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Radiology. 2020 Aug;296(2):E86-E96
pubmed: 32301647
Diagn Microbiol Infect Dis. 2020 Sep;98(1):115094
pubmed: 32623267
Laryngoscope. 2014 Jul;124(7):1678-81
pubmed: 24307612
Int Immunopharmacol. 2020 Jul;84:106504
pubmed: 32304994
Acad Radiol. 2020 Jun;27(6):901
pubmed: 32335002
Clin Immunol. 2020 May;214:108393
pubmed: 32222466